<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02269111</url>
  </required_header>
  <id_info>
    <org_study_id>VICC NEU1424</org_study_id>
    <secondary_id>NCI-2014-01907</secondary_id>
    <secondary_id>VICC NEU1424</secondary_id>
    <secondary_id>P30CA068485</secondary_id>
    <nct_id>NCT02269111</nct_id>
  </id_info>
  <brief_title>Quantitative MRI in Assessing Disease in Patients With Brain Tumors</brief_title>
  <official_title>Quantitative High-Field Magnetic Resonance Imaging (MRI) for Assessing Brain Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt-Ingram Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt-Ingram Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot clinical trial studies quantitative magnetic resonance imaging (MRI) at 3 Tesla in&#xD;
      assessing disease in patients with tumors that have spread to the brain (brain metastases).&#xD;
      In addition to routine care brain imaging of the brain, this study will include advanced&#xD;
      multiparametric MRI sequences to measure vascular, cellular, and molecular properties of the&#xD;
      tumor. Performing extra scans during MRI provides more information about the metastases and&#xD;
      may better predict treatment response.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To correlate pre-treatment measures of biophysical parameters in metastases-obtained using&#xD;
      advanced, quantitative MRI techniques in patients receiving standard-of-care (SOC) therapy&#xD;
      for 1-4 brain metastases-with treatment-induced changes in lesion size, time-to-progression&#xD;
      (TTP), and overall survival (OS).&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo hybrid 3 Tesla MRI examination that includes standard MRI sequences,&#xD;
      diffusion-weighted (DW)-MRI, chemical exchange saturation transfer (CEST), and combined&#xD;
      dynamic contrast enhanced (DCE)-MRI/dynamic susceptibility contrast (DSC)-MRI at baseline.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Change in PI and funding&#xD;
  </why_stopped>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">May 2018</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Volume transfer constant (Ktrans), as measured by DCE-MRI</measure>
    <time_frame>Baseline</time_frame>
    <description>The ability of pre-treatment estimates of Ktrans to predict objective tumor response by Response Evaluation Criteria in Solid Tumors or Macdonald criteria after therapy will be assessed using the proportional odds model.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Amide proton transfer asymmetry (APTasym) as measured by CEST</measure>
    <time_frame>Baseline</time_frame>
    <description>Cox proportional hazards regression will be used to assess the association of APTasym with change in tumor size.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent diffusion coefficient (ADC), as measured by DW-MRI</measure>
    <time_frame>Baseline</time_frame>
    <description>Cox proportional hazards regression will be used to assess the association of ADC with change in tumor size.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extravascular extracellular volume fraction (Ve), as measured by DCE-MRI</measure>
    <time_frame>Baseline</time_frame>
    <description>Cox proportional hazards regression will be used to assess the association of Ve with change in tumor size.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma volume fraction (Vp), as measured by DCE-MRI</measure>
    <time_frame>Baseline</time_frame>
    <description>Cox proportional hazards regression will be used to assess the association of Vp with change in tumor size.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral blood volume (CBV), as measured by DSC-MRI</measure>
    <time_frame>Baseline</time_frame>
    <description>Cox proportional hazards regression will be used to assess the association of CBV with change in tumor size.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral blood flow (CBF), as measured by DSC-MRI</measure>
    <time_frame>Baseline</time_frame>
    <description>Cox proportional hazards regression will be used to assess the association of CBF with change in tumor size.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean transit time (MTT), as measured by DSC-MRI</measure>
    <time_frame>Baseline</time_frame>
    <description>Cox proportional hazards regression will be used to assess the association of MTT with change in tumor size.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Tumors Metastatic to Brain</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Diagnostic (hybrid MRI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo hybrid 3 Tesla MRI examination that includes standard MRI sequences, DW-MRI, CEST, and combined DCE-MRI/DSC-MRI at baseline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>diffusion-weighted magnetic resonance imaging</intervention_name>
    <description>Undergo DW-MRI</description>
    <arm_group_label>Diagnostic (hybrid MRI)</arm_group_label>
    <other_name>diffusion-weighted MRI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>chemical exchange saturation transfer magnetic resonance imaging</intervention_name>
    <description>Undergo CEST-MRI</description>
    <arm_group_label>Diagnostic (hybrid MRI)</arm_group_label>
    <other_name>CEST MRI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>dynamic contrast-enhanced magnetic resonance imaging</intervention_name>
    <description>Undergo DCE-MRI</description>
    <arm_group_label>Diagnostic (hybrid MRI)</arm_group_label>
    <other_name>DCE-MRI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>dynamic susceptibility contrast-enhanced magnetic resonance imaging</intervention_name>
    <description>Undergo DSC-MRI</description>
    <arm_group_label>Diagnostic (hybrid MRI)</arm_group_label>
    <other_name>DSC-MRI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must sign an Institutional Review Board (IRB)-approved informed consent&#xD;
             document&#xD;
&#xD;
          -  Patients must have been diagnosed with one of the following:&#xD;
&#xD;
               -  Primary brain tumor (glioma, GBM etc); or&#xD;
&#xD;
               -  Up to 10 brain metastases&#xD;
&#xD;
          -  Patients must have been diagnosed with 1-4 brain metastases&#xD;
&#xD;
          -  At least one of the brain metastases must measure 5 mm (or more) in short axis&#xD;
             diameter in the axial plane&#xD;
&#xD;
          -  Patients must be scheduled to undergo standard brain cancer interventions:&#xD;
&#xD;
               -  Chemotherapy or targeted antiangiogenic therapy, in the case of primary brain&#xD;
                  tumor; or&#xD;
&#xD;
               -  Stereotaxic radiotherapy (SRS) or whole brain radiotherapy (WBRT), in the case of&#xD;
                  brain metastases.&#xD;
&#xD;
          -  Patients must be scheduled to receive a 3-Tesla (3T) MRI exam as part of their&#xD;
             standard of care (this exam will be modified to also include pulse sequences with are&#xD;
             for research only)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have received previous treatment (chemotherapy or radiotherapy) for any&#xD;
             brain tumor (primary or metastatic).&#xD;
&#xD;
          -  Patients who are scheduled to receive a 1.5T MRI exam&#xD;
&#xD;
          -  Patients incapable of giving informed written consent, due to mental disability,&#xD;
             altered mental status, confusion, cognitive impairment, or psychiatric disorders.&#xD;
&#xD;
          -  Patients scoring 14.5 or lower on the University of California, San Diego Brief&#xD;
             Assessment of Capacity to Consent (UBACC) questionnaire will not be allowed on the&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert Attia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt-Ingram Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://vicc.org/ct/</url>
    <description>Vanderbilt-Ingram Cancer Center, Find a Clinical Trial</description>
  </link>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>October 15, 2014</study_first_submitted>
  <study_first_submitted_qc>October 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2014</study_first_posted>
  <last_update_submitted>May 25, 2018</last_update_submitted>
  <last_update_submitted_qc>May 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt-Ingram Cancer Center</investigator_affiliation>
    <investigator_full_name>Albert Attia</investigator_full_name>
    <investigator_title>Assistant Professor of Radiation Oncology; Radiation Oncologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

